NorthView Acquisition, a blank check company targeting small cap healthcare businesses in North America, Europe, and APAC, filed on Thursday with the SEC to raise up to $180 million.
The New York, NY-based company plans to raise $180 million by offering 18 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. At the proposed deal size, NorthView Acquisition would command a market value of $228 million.
The company was formed by CEO and Director Jack Stover, whose former roles include serving as CEO of Interpace Biosciences and Antares Pharma, and CFO and Director Fred Knechtel, who previously served as the CFO of Interpace and GENEWIZ. The company plans to target small cap businesses domiciled in North America, Europe and/or the APAC regions that are developing assets in the biopharmaceutical, medical technology/medical device, and diagnostics spaces.
NorthView Acquisition was founded in 2021 and plans to list on the Nasdaq, but has not selected a symbol yet (RC ticker: NVAU.RC). I-Bankers Securities is the sole bookrunner on the deal.
